| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| MicroRNAs | 7 | 2018 | 447 | 1.190 |
Why?
|
| Gene Expression Regulation, Neoplastic | 7 | 2018 | 756 | 1.030 |
Why?
|
| Breast Neoplasms | 9 | 2020 | 1536 | 0.830 |
Why?
|
| Transcription Factors | 4 | 2014 | 753 | 0.770 |
Why?
|
| Colorectal Neoplasms | 3 | 2018 | 561 | 0.740 |
Why?
|
| Epithelial-Mesenchymal Transition | 3 | 2014 | 135 | 0.610 |
Why?
|
| Oxidoreductases | 3 | 2006 | 117 | 0.530 |
Why?
|
| Proto-Oncogene Proteins c-ets | 4 | 2014 | 79 | 0.510 |
Why?
|
| Fluorouracil | 2 | 2020 | 130 | 0.510 |
Why?
|
| Proto-Oncogene Protein c-ets-1 | 2 | 2013 | 65 | 0.500 |
Why?
|
| Peroxiredoxins | 3 | 2013 | 34 | 0.460 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2013 | 35 | 0.440 |
Why?
|
| Azo Compounds | 4 | 2006 | 33 | 0.430 |
Why?
|
| Calcitriol | 1 | 2013 | 106 | 0.430 |
Why?
|
| Cell Line, Tumor | 12 | 2018 | 1851 | 0.420 |
Why?
|
| Glutathione | 5 | 2006 | 343 | 0.420 |
Why?
|
| Snail Family Transcription Factors | 4 | 2018 | 31 | 0.410 |
Why?
|
| 4-Aminobenzoic Acid | 4 | 2006 | 30 | 0.340 |
Why?
|
| Protein Biosynthesis | 1 | 2008 | 181 | 0.300 |
Why?
|
| Prodrugs | 2 | 2005 | 54 | 0.290 |
Why?
|
| Tumor Microenvironment | 2 | 2021 | 213 | 0.280 |
Why?
|
| Glycation End Products, Advanced | 2 | 2018 | 125 | 0.260 |
Why?
|
| para-Aminobenzoates | 4 | 2006 | 27 | 0.260 |
Why?
|
| Rectal Neoplasms | 2 | 2020 | 75 | 0.260 |
Why?
|
| Cell Movement | 6 | 2014 | 630 | 0.260 |
Why?
|
| Phenotype | 6 | 2021 | 947 | 0.250 |
Why?
|
| Neoplasms | 3 | 2013 | 1667 | 0.240 |
Why?
|
| Receptors, Estrogen | 3 | 2020 | 142 | 0.240 |
Why?
|
| Glutathione Transferase | 2 | 2004 | 166 | 0.230 |
Why?
|
| Nitric Oxide Donors | 1 | 2004 | 54 | 0.230 |
Why?
|
| Nitric Oxide | 3 | 2006 | 382 | 0.230 |
Why?
|
| RNA, Messenger | 3 | 2013 | 1664 | 0.220 |
Why?
|
| Antioxidants | 1 | 2005 | 304 | 0.220 |
Why?
|
| Isoenzymes | 1 | 2004 | 308 | 0.210 |
Why?
|
| Oxidative Stress | 6 | 2006 | 718 | 0.210 |
Why?
|
| Protein Processing, Post-Translational | 3 | 2013 | 284 | 0.200 |
Why?
|
| Humans | 27 | 2021 | 68618 | 0.200 |
Why?
|
| Models, Biological | 5 | 2020 | 981 | 0.190 |
Why?
|
| 3' Untranslated Regions | 2 | 2013 | 56 | 0.190 |
Why?
|
| Cancer Survivors | 2 | 2020 | 146 | 0.180 |
Why?
|
| Mitogen-Activated Protein Kinases | 4 | 2005 | 250 | 0.170 |
Why?
|
| Schizosaccharomyces | 3 | 2005 | 31 | 0.170 |
Why?
|
| Fluorescent Antibody Technique | 3 | 2015 | 282 | 0.170 |
Why?
|
| Students | 1 | 2021 | 233 | 0.170 |
Why?
|
| Disease Susceptibility | 1 | 2020 | 179 | 0.160 |
Why?
|
| Breast | 1 | 2020 | 137 | 0.160 |
Why?
|
| Oncogenes | 1 | 2019 | 71 | 0.160 |
Why?
|
| Precision Medicine | 1 | 2020 | 111 | 0.160 |
Why?
|
| Animals | 12 | 2020 | 20881 | 0.160 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2020 | 235 | 0.160 |
Why?
|
| Colonic Neoplasms | 1 | 2021 | 299 | 0.160 |
Why?
|
| Biomedical Research | 1 | 2021 | 310 | 0.150 |
Why?
|
| Tumor Cells, Cultured | 2 | 2013 | 852 | 0.150 |
Why?
|
| Phosphoproteins | 1 | 2019 | 202 | 0.150 |
Why?
|
| Radiation Tolerance | 1 | 2018 | 30 | 0.150 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2019 | 214 | 0.150 |
Why?
|
| Oxidoreductases Acting on Sulfur Group Donors | 3 | 2006 | 20 | 0.150 |
Why?
|
| Cell Proliferation | 4 | 2019 | 1174 | 0.150 |
Why?
|
| Neoplastic Stem Cells | 1 | 2018 | 84 | 0.140 |
Why?
|
| Hydrogen Peroxide | 4 | 2006 | 168 | 0.140 |
Why?
|
| Transfection | 2 | 2019 | 782 | 0.140 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2020 | 304 | 0.140 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 468 | 0.140 |
Why?
|
| Prostatic Neoplasms | 2 | 2014 | 778 | 0.140 |
Why?
|
| Life Style | 1 | 2018 | 338 | 0.140 |
Why?
|
| Body Mass Index | 1 | 2020 | 867 | 0.140 |
Why?
|
| Diet | 1 | 2020 | 514 | 0.140 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2018 | 332 | 0.140 |
Why?
|
| Peroxidases | 3 | 2005 | 28 | 0.140 |
Why?
|
| Blotting, Western | 3 | 2015 | 954 | 0.140 |
Why?
|
| Mice | 8 | 2020 | 8474 | 0.140 |
Why?
|
| Healthcare Disparities | 1 | 2020 | 378 | 0.130 |
Why?
|
| Cadherins | 2 | 2013 | 93 | 0.130 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2015 | 710 | 0.130 |
Why?
|
| Promoter Regions, Genetic | 2 | 2018 | 615 | 0.120 |
Why?
|
| Schizosaccharomyces pombe Proteins | 3 | 2005 | 31 | 0.120 |
Why?
|
| Oxidation-Reduction | 3 | 2013 | 567 | 0.120 |
Why?
|
| Recurrence | 2 | 2019 | 948 | 0.120 |
Why?
|
| Glutathione S-Transferase pi | 2 | 2005 | 53 | 0.120 |
Why?
|
| HT29 Cells | 1 | 2014 | 42 | 0.120 |
Why?
|
| Transcription, Genetic | 3 | 2007 | 562 | 0.120 |
Why?
|
| Neoplasms, Experimental | 1 | 2015 | 118 | 0.120 |
Why?
|
| HCT116 Cells | 1 | 2014 | 63 | 0.120 |
Why?
|
| Exercise | 1 | 2020 | 658 | 0.120 |
Why?
|
| Neoplasm Metastasis | 2 | 2013 | 306 | 0.120 |
Why?
|
| Disease Progression | 3 | 2013 | 1038 | 0.120 |
Why?
|
| Neovascularization, Pathologic | 1 | 2015 | 183 | 0.110 |
Why?
|
| Proto-Oncogene Protein c-fli-1 | 1 | 2014 | 106 | 0.110 |
Why?
|
| Calcium Channel Agonists | 1 | 2013 | 18 | 0.110 |
Why?
|
| Mice, Transgenic | 2 | 2014 | 1033 | 0.110 |
Why?
|
| Vimentin | 1 | 2013 | 47 | 0.110 |
Why?
|
| Receptors, Calcitriol | 1 | 2013 | 49 | 0.110 |
Why?
|
| Gamma Rays | 1 | 2013 | 64 | 0.110 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2013 | 30 | 0.110 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2013 | 18 | 0.110 |
Why?
|
| Dual Specificity Phosphatase 1 | 1 | 2012 | 22 | 0.110 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 209 | 0.110 |
Why?
|
| Herpesvirus 8, Human | 1 | 2012 | 24 | 0.110 |
Why?
|
| Multigene Family | 1 | 2013 | 93 | 0.110 |
Why?
|
| Protein Interaction Mapping | 1 | 2013 | 62 | 0.110 |
Why?
|
| Staphylococcus epidermidis | 1 | 2012 | 12 | 0.100 |
Why?
|
| Tumor Burden | 1 | 2013 | 132 | 0.100 |
Why?
|
| Enzyme Activation | 5 | 2005 | 791 | 0.100 |
Why?
|
| Cell Adhesion | 1 | 2013 | 324 | 0.100 |
Why?
|
| Female | 9 | 2021 | 38074 | 0.100 |
Why?
|
| Host-Pathogen Interactions | 1 | 2012 | 69 | 0.100 |
Why?
|
| Gene Expression Regulation, Bacterial | 1 | 2012 | 50 | 0.100 |
Why?
|
| Catheters, Indwelling | 1 | 2012 | 72 | 0.100 |
Why?
|
| Biofilms | 1 | 2012 | 72 | 0.100 |
Why?
|
| Homeostasis | 1 | 2013 | 291 | 0.100 |
Why?
|
| Signal Transduction | 4 | 2018 | 2689 | 0.090 |
Why?
|
| Trans-Activators | 1 | 2012 | 237 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2013 | 331 | 0.090 |
Why?
|
| Biomarkers, Tumor | 1 | 2014 | 508 | 0.090 |
Why?
|
| Bacterial Proteins | 1 | 2012 | 245 | 0.090 |
Why?
|
| Fibroblasts | 1 | 2015 | 902 | 0.090 |
Why?
|
| Gene Expression Profiling | 2 | 2012 | 498 | 0.090 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 2 | 2006 | 13 | 0.090 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2011 | 282 | 0.090 |
Why?
|
| Protein Tyrosine Phosphatases | 2 | 2006 | 56 | 0.080 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 2 | 2006 | 272 | 0.080 |
Why?
|
| Disease Models, Animal | 2 | 2015 | 2550 | 0.080 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 2 | 2005 | 82 | 0.080 |
Why?
|
| Gene Expression Regulation, Fungal | 2 | 2005 | 32 | 0.080 |
Why?
|
| Cysteine | 2 | 2005 | 112 | 0.070 |
Why?
|
| Mice, SCID | 2 | 2006 | 238 | 0.070 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 2 | 2004 | 140 | 0.070 |
Why?
|
| Friedreich Ataxia | 1 | 2005 | 6 | 0.070 |
Why?
|
| Peroxides | 1 | 2005 | 23 | 0.060 |
Why?
|
| Actins | 1 | 2006 | 249 | 0.060 |
Why?
|
| Nitroso Compounds | 1 | 2004 | 16 | 0.060 |
Why?
|
| Leukotriene C4 | 1 | 2004 | 7 | 0.060 |
Why?
|
| Multidrug Resistance-Associated Proteins | 1 | 2004 | 24 | 0.060 |
Why?
|
| 3T3 Cells | 1 | 2004 | 124 | 0.060 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2004 | 120 | 0.060 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2004 | 134 | 0.060 |
Why?
|
| Phosphorylation | 3 | 2019 | 1200 | 0.060 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2015 | 507 | 0.060 |
Why?
|
| Oxygen | 1 | 2005 | 386 | 0.050 |
Why?
|
| Cell Division | 1 | 2004 | 541 | 0.050 |
Why?
|
| Piperazines | 1 | 2004 | 206 | 0.050 |
Why?
|
| Biomarkers | 2 | 2018 | 1593 | 0.050 |
Why?
|
| Parkinson Disease | 1 | 2005 | 272 | 0.050 |
Why?
|
| Immunohistochemistry | 2 | 2015 | 1174 | 0.050 |
Why?
|
| Genes, MHC Class I | 1 | 2021 | 14 | 0.050 |
Why?
|
| Genes, MHC Class II | 1 | 2021 | 29 | 0.050 |
Why?
|
| Cell Nucleus | 3 | 2011 | 305 | 0.050 |
Why?
|
| Mentors | 1 | 2021 | 81 | 0.050 |
Why?
|
| Faculty | 1 | 2021 | 56 | 0.050 |
Why?
|
| Immunophenotyping | 1 | 2021 | 110 | 0.050 |
Why?
|
| Down-Regulation | 2 | 2012 | 447 | 0.050 |
Why?
|
| MAP Kinase Signaling System | 1 | 2002 | 247 | 0.050 |
Why?
|
| Immunity, Cellular | 1 | 2021 | 80 | 0.050 |
Why?
|
| Immunity | 1 | 2021 | 67 | 0.050 |
Why?
|
| Cetuximab | 1 | 2020 | 19 | 0.040 |
Why?
|
| Organoids | 1 | 2020 | 42 | 0.040 |
Why?
|
| Heterografts | 1 | 2020 | 70 | 0.040 |
Why?
|
| Neoadjuvant Therapy | 1 | 2020 | 104 | 0.040 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2020 | 78 | 0.040 |
Why?
|
| Everolimus | 1 | 2019 | 26 | 0.040 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2019 | 37 | 0.040 |
Why?
|
| Gene Amplification | 1 | 2019 | 71 | 0.040 |
Why?
|
| Linear Models | 1 | 2021 | 521 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2019 | 54 | 0.040 |
Why?
|
| MCF-7 Cells | 1 | 2019 | 80 | 0.040 |
Why?
|
| RNA, Viral | 2 | 2012 | 93 | 0.040 |
Why?
|
| B-Lymphocytes | 1 | 2021 | 329 | 0.040 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2021 | 266 | 0.040 |
Why?
|
| Gene Knockdown Techniques | 1 | 2019 | 196 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2018 | 111 | 0.040 |
Why?
|
| Tamoxifen | 1 | 2018 | 62 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2019 | 349 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 2 | 2011 | 369 | 0.040 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2019 | 118 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 2 | 2015 | 2791 | 0.040 |
Why?
|
| Antineoplastic Agents | 1 | 2006 | 1070 | 0.040 |
Why?
|
| Gene Expression | 1 | 2021 | 770 | 0.040 |
Why?
|
| Cell Self Renewal | 1 | 2018 | 13 | 0.040 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2018 | 99 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2019 | 536 | 0.040 |
Why?
|
| Cell Cycle Proteins | 1 | 2019 | 230 | 0.040 |
Why?
|
| Macrophages | 1 | 2021 | 647 | 0.040 |
Why?
|
| Sex Factors | 1 | 2021 | 1266 | 0.040 |
Why?
|
| RNA Interference | 1 | 2018 | 266 | 0.040 |
Why?
|
| Neoplasm Staging | 1 | 2018 | 800 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2018 | 951 | 0.030 |
Why?
|
| Age Factors | 1 | 2021 | 1864 | 0.030 |
Why?
|
| Male | 4 | 2021 | 37321 | 0.030 |
Why?
|
| Umbilical Veins | 1 | 2015 | 54 | 0.030 |
Why?
|
| Mutation | 1 | 2020 | 1213 | 0.030 |
Why?
|
| Mice, Mutant Strains | 1 | 2014 | 166 | 0.030 |
Why?
|
| Prognosis | 1 | 2019 | 2093 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2015 | 489 | 0.030 |
Why?
|
| Aged | 2 | 2021 | 14862 | 0.030 |
Why?
|
| Pancreatitis-Associated Proteins | 2 | 2005 | 3 | 0.030 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2014 | 114 | 0.030 |
Why?
|
| Basic-Leucine Zipper Transcription Factors | 2 | 2005 | 19 | 0.030 |
Why?
|
| Fungal Proteins | 2 | 2005 | 37 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2014 | 223 | 0.030 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2015 | 268 | 0.030 |
Why?
|
| Oxidants | 2 | 2004 | 48 | 0.030 |
Why?
|
| Bacteriolysis | 1 | 2012 | 2 | 0.030 |
Why?
|
| Amino Acid Sequence | 2 | 2005 | 1083 | 0.030 |
Why?
|
| Bacterial Adhesion | 1 | 2012 | 33 | 0.030 |
Why?
|
| RNA, Bacterial | 1 | 2012 | 30 | 0.030 |
Why?
|
| Molecular Sequence Data | 2 | 2005 | 1447 | 0.030 |
Why?
|
| Middle Aged | 2 | 2021 | 21147 | 0.020 |
Why?
|
| DNA, Bacterial | 1 | 2012 | 150 | 0.020 |
Why?
|
| Cells, Cultured | 2 | 2007 | 2673 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2011 | 312 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2005 | 1745 | 0.020 |
Why?
|
| DNA-Binding Proteins | 2 | 2005 | 700 | 0.020 |
Why?
|
| Receptors, Urokinase Plasminogen Activator | 1 | 2008 | 14 | 0.020 |
Why?
|
| Cell Line | 1 | 2012 | 1752 | 0.020 |
Why?
|
| Risk Factors | 1 | 2018 | 5731 | 0.020 |
Why?
|
| Cytoskeleton | 1 | 2008 | 84 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2008 | 261 | 0.020 |
Why?
|
| Models, Genetic | 1 | 2007 | 161 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2008 | 320 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2012 | 1293 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2018 | 7029 | 0.020 |
Why?
|
| Drug Stability | 1 | 2006 | 71 | 0.020 |
Why?
|
| Solubility | 1 | 2006 | 134 | 0.020 |
Why?
|
| Hydrolysis | 1 | 2006 | 144 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2006 | 122 | 0.020 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2006 | 111 | 0.020 |
Why?
|
| Mice, Inbred NOD | 1 | 2006 | 138 | 0.020 |
Why?
|
| Crystallography, X-Ray | 1 | 2006 | 190 | 0.020 |
Why?
|
| Proteomics | 1 | 2007 | 246 | 0.020 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2005 | 55 | 0.020 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2005 | 95 | 0.020 |
Why?
|
| Catalysis | 1 | 2005 | 123 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2005 | 132 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 2006 | 420 | 0.020 |
Why?
|
| MAP Kinase Kinase 4 | 1 | 2004 | 33 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 8 | 1 | 2004 | 17 | 0.010 |
Why?
|
| Macromolecular Substances | 1 | 2004 | 122 | 0.010 |
Why?
|
| Sulfides | 1 | 2004 | 43 | 0.010 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2005 | 123 | 0.010 |
Why?
|
| Binding Sites | 1 | 2004 | 631 | 0.010 |
Why?
|
| Base Sequence | 1 | 2004 | 1015 | 0.010 |
Why?
|
| Activating Transcription Factor 1 | 1 | 2002 | 2 | 0.010 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2002 | 34 | 0.010 |
Why?
|
| Proteins | 1 | 2005 | 474 | 0.010 |
Why?
|
| Protein Binding | 1 | 2004 | 1027 | 0.010 |
Why?
|
| Inflammation | 1 | 2007 | 1030 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2004 | 1692 | 0.010 |
Why?
|
| Time Factors | 1 | 2005 | 4655 | 0.010 |
Why?
|